Unlocking the Potential: Sulforaphane vs. TNBC
Board Location: #103
Discipline: Chemistry and Chemical Sciences
Subcategory: Cancer Research
Session: 1
Endia Douglas - University of Arkansas at Pine Bluff
Co-Author(s): Dr. Zeeshan Habeeb, University of Arkansas at Pine Bluff, Pine Bluff, AR
Triple-negative breast cancer (TNBC) remains a formidable challenge in oncology due to its aggressive nature and limited treatment options. However, a natural compound derived from cruciferous vegetables, sulforaphane, has demonstrated anti-cancer properties. We use this information to assess the bioactivity of the encapsulated sulforaphane-peptide construct and its potential as a treatment for TNBC. Our approach involved the synthesis of the sulforaphane-peptide construct and its subsequent evaluation in a toxicity study using the 4T1 cell line. The results of our toxicity study demonstrated promising outcomes, indicating the construct’s ability to exert significant cytotoxic effects on 4T1 TNBC cells while sparing normal cells. These findings suggest that the sulforaphane-peptide construct possesses good bioactivity against TNBC, making it a potential candidate for further development as an effective therapeutic agent.
Funder Acknowledgement(s): Targeted Infusion Project, The National Research Foundation (NSF)
Faculty Advisor: Dr. Anissa Buckner, bucknera@uapb.edu
Role: The synthesis of the encapsulated sulforaphane-peptide, which includes measuring out the resin used, creating the peptide, and the cleavage process.